Dr. Marwan O. Kaskas, MD

Dr. Kaskas practices at Fmc Dialysis Services South Shreveport in Shreveport, Louisiana.

Dr. Kaskas' NPI, 1831184407, was assigned on September 20, 2005. Dr. Kaskas holds Louisiana license 09084R.

Dr. Kaskas' primary practice is Fmc Dialysis Services South Shreveport, at 1800 Buckner St, Shreveport, LA 71101 in Caddo Parish. The practice phone is (318) 868-8320.

Dr. Kaskas' primary practice is Fmc Dialysis Services South Shreveport in Shreveport, Louisiana. Dr. Kaskas is also affiliated with Willis Knighton North. The medical group on file is Northwest Louisiana Nephrology. Dmand AI also links Dr. Kaskas to 5 more hospitals, 3 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kaskas practices, 10 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Kaskas' primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Kaskas is licensed in Louisiana.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia, kidney disease and parathyroid gland disorder among the conditions Dr. Kaskas treats.

CMS data shows 2,489 Medicare services from Dr. Kaskas across 17 procedure codes in 2024, for 724 Medicare patients. Medicare paid $218,892 for them.

CMS counts 724 Medicare patients who saw Dr. Kaskas in 2024. The largest group is 65 to 74, with 271 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 25% are also on Medicaid. Their average risk score is 4.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kaskas' median patient age at 70, with 47% women.

In 2024, Dr. Kaskas wrote 2,556 Medicare Part D claims for 325 patients. 82% of them were for generic drugs. CMS names the drug for 2,247 of them, across 46 drugs with 11 or more claims each, at $386,460 in total drug cost. In 2023, CMS named 2,315 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kaskas for performance year 2024, reported as part of a group. Dr. Kaskas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Kaskas, published from 2006 to 2019. 2019 was the busiest year, with 2. The most frequent topics are Ferric Compounds. Dr. Kaskas' most frequent co-authors are Eric J. Lawitz, MD, Rajiv Agarwal, MD and Rajiv Agarwal.

Dmand AI links Dr. Kaskas to 4 clinical trials, 2 of them phase 3 studies. Conditions studied include Polycystic Kidney, Autosomal Dominant, Glomerulonephritis, IGA and Nephritis, Hereditary. Biogen sponsors the most, 3.

CMS Open Payments shows 669 general payments to Dr. Kaskas from 40 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Amgen Inc. paid the most, $11,500.

Dmand AI lists 2 awards for Dr. Kaskas, most recently Regional Top Doctor in 2014.

Dr. Kaskas is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.